Monopar Therapeutics (NASDAQ:MNPR) Releases Quarterly Earnings Results, Beats Expectations By $0.60 EPS

Monopar Therapeutics (NASDAQ:MNPR) issued its quarterly earnings results on Thursday. The company reported ($0.46) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.06) by $0.60, Zacks reports.

Monopar Therapeutics Trading Down 2.8%

MNPR opened at $59.27 on Friday. The company has a 50 day moving average of $56.96 and a 200 day moving average of $65.82. The company has a market cap of $397.11 million, a PE ratio of -31.19 and a beta of 1.49. Monopar Therapeutics has a 12 month low of $28.40 and a 12 month high of $105.00.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Russell Investments Group Ltd. bought a new position in Monopar Therapeutics in the 3rd quarter valued at $28,000. BNP Paribas Financial Markets boosted its holdings in Monopar Therapeutics by 100.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 696 shares of the company’s stock valued at $57,000 after purchasing an additional 349 shares during the period. Meeder Asset Management Inc. bought a new position in Monopar Therapeutics in the 4th quarter valued at $65,000. JPMorgan Chase & Co. boosted its holdings in Monopar Therapeutics by 1,821.0% in the 2nd quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company’s stock valued at $69,000 after purchasing an additional 1,821 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in Monopar Therapeutics in the 2nd quarter valued at $80,000. 1.83% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on MNPR. Cantor Fitzgerald restated an “overweight” rating on shares of Monopar Therapeutics in a research note on Wednesday, January 21st. Wall Street Zen upgraded shares of Monopar Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 9th. BTIG Research restated a “buy” rating and set a $104.00 price target on shares of Monopar Therapeutics in a research note on Monday, February 23rd. Chardan Capital restated a “buy” rating and set a $100.00 price target on shares of Monopar Therapeutics in a research note on Monday, March 30th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Monopar Therapeutics in a research note on Tuesday, April 21st. Two analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Monopar Therapeutics has an average rating of “Buy” and a consensus price target of $107.00.

About Monopar Therapeutics

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.